Sanofi SA
1SAN
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
We plan to raise our fair value estimate of Coca-Cola stock.
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,321.10 | 10.80 | -0.12% |
| CAC 40 | 8,241.93 | 16.93 | -0.21% |
| DAX 40 | 24,324.40 | 5.63 | -0.02% |
| Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
| FTSE 100 | 9,510.16 | 83.17 | 0.88% |
| HKSE | 25,781.77 | 245.78 | -0.94% |
| NASDAQ | 22,953.67 | 36.88 | -0.16% |
| Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
| NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
| S&P 500 | 6,735.35 | 0.22 | 0.00% |
| S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
| SSE Composite Index | 3,913.76 | 2.57 | -0.07% |